COVID-19 vaccine uptake and vaccine hesitancy in rheumatic disease patients receiving immunomodulatory therapies in community practice settings
Arthritis Rheumatol
.
2022 Jun;74(6):1091-1092.
doi: 10.1002/art.42067.
Epub 2022 Apr 27.
Authors
Stephanie S Ledbetter
1
,
Fenglong Xie
1
,
Gary Cutter
1
,
Kenneth G Saag
1
,
Lesley Jackson
1
,
Maria I Danila
1
,
Patrick Stewart
2
,
Michael George
3
,
William Benjamin Nowell
4
,
Ted Mikuls
5
,
Kevin Winthrop
6
,
Jeffrey R Curtis
1
Affiliations
1
University of Alabama at Birmingham.
2
Bendcare, Boca Raton, FL.
3
University of Pennsylvania Medical Center, Philadelphia, PA.
4
Global Healthy Living Foundation, Nyack, NY.
5
University of Nebraska Medical Center and VA Nebraska-Western Iowa Health Care System, Omaha, NE.
6
Oregon Health & Science University, Portland, OR.
PMID:
35235715
PMCID:
PMC9011772
DOI:
10.1002/art.42067
No abstract available
Publication types
Letter
MeSH terms
COVID-19 Vaccines
COVID-19* / prevention & control
Humans
Immunomodulation
Rheumatic Diseases* / drug therapy
Vaccination
Vaccination Hesitancy
Substances
COVID-19 Vaccines
Grants and funding
P30 AR072583/AR/NIAMS NIH HHS/United States
T32 AR069516/AR/NIAMS NIH HHS/United States